CytomX Therapeutics, Inc. Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax
CytomX Therapeutics, Inc. (CTMX) had Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax of $110.00 thousand as of 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Notes › Investments
us-gaap:AvailableForSaleSecuritiesAccumulatedGrossUnrealizedGainBeforeTax · last filed 2020-02-27
- 2019-12-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $110.00K.
- 2019-09-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $167.00K.
- 2019-06-30: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $268.00K.
- 2019-03-31: Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax $131.00K.
| Period end | Available-for-sale Securities, Accumulated Gross Unrealized Gain, before Tax |
|---|---|
| 2019-12-31 | $110.00K 10-K · filed 2020-02-27 |
| 2019-09-30 | $167.00K 10-Q · filed 2019-11-07 |
| 2019-06-30 | $268.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $131.00K 10-Q · filed 2019-05-09 |
| 2016-12-31 | $8.00K 10-K · filed 2017-03-02 |
| 2016-09-30 | $48.00K 10-Q · filed 2016-11-03 |
| 2016-06-30 | $79.00K 10-Q · filed 2016-08-03 |
| 2016-03-31 | $31.00K 10-Q · filed 2016-05-06 |
| 2015-09-30 | $10.00K 10-Q · filed 2015-11-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |